Braveheart Bio, Inc. (BRVE)

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Hypertrophic cardiomyopathy is an inherited condition in which the heart muscle becomes abnormally thick and stiff.

The company's lead candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor designed to reduce excessive heart muscle contraction, and it is being studied in both obstructive and non-obstructive forms of the disease. Braveheart Bio was incorporated in 2024, is headquartered in San Francisco, California, and completed its initial public offering on Nasdaq in August 2026.